Dear Sir,
Further to the recent report on the use of recombinant insulin-like growth factor I (rhIGF-I) to improve lipid profile in Type 2 diabetes [1] we would like to report a new finding noted during the therapeutic use of rhIGF-I. There is evidence to support a role for IGF-I in the regulation of erythropoesis. Serum IGF-I but not erythropoetin concentrations correlate well with haematocrit values in uraemic patients [2] . RhlGF-I has been shown to stimulate erythropoesis in hypophysectomised rats [3] . In this study rhIGF-I infusions given subcutaneously caused a significant rise in erythropoetin concentrations. The effect of rhIGF-I infusions on erythropoetin concentrations in normal humans has not to our knowledge been studied.
RhIGF-I has been used therapeutically in extreme insulin resistance where its effects on lipids and lipoproteins have been described [4, 5] . Subsequent larger studies have suggested a clinical role where insulin treatment is ineffective [6] . We have studied the effect of rhIGF-I on erythropoetin concentrations in a 17-year-old boy with the Mendenhall syndrome, a rare extreme insulin resistant state. Venous sampling was performed on two occasions prior to, during and after 40 mg rhIGF-I given intravenously by an infusion pump over 48 h. Erythropoetin was measured in plasma by EPO-Trac TM Assay (Incstar Ltd., Wokingham, UK). Erythropoetin concentrations rose from 1t.6 to 43.7 mU/ml (reference interval: 15-30 mU/ml). Comparison of erythropoetin concentrations prior to and after the first 24 h of rhlGF-I infusion showed a significant rise from 22.0 + 3.2 to 33.4 + 3.1 mU/ml, p < 0.02 (mean and SEM, n = 6, Fig. 1 ). RhIGF-I by infusion appears to increase erythropoetin concentrations in this rare condition. The mechanism by which rhIGF-I has this effect is not clear but in animal studies it stimulates erythropoetin production [3] . Further studies of the effect of rhIGF-I on erythropoetin concentrations in normal individuals would be of interest. Recombinant growth hormone has been used in uraemic children with increased IGF-I concentrations noted and sfight improvement of anaemia [7] . Given that rhIGF-I also has growth promoting effects our finding could suggest that therapeutic use may be of potential benefit in growth retarded, anaemic children with chronic renal failure. 
